Best of the year: Advanced breast cancer in 2023

Ilana Schlam; Mariana Chavez-MacGregor

doi:10.1016/j.breast.2024.103677

Best of the year: Advanced breast cancer in 2023

Breast. 2024 Apr:74:103677. doi: 10.1016/j.breast.2024.103677. Epub 2024 Feb 14.

Authors

Ilana Schlam¹, Mariana Chavez-MacGregor²

Affiliations

¹ Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA; Tufts University, Boston, MA, USA.
² Health Services Research Department, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Breast Medical Oncology Department, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mchavez1@mdanderson.org.

Abstract

•
This article reviews some of the most clinically relevant data related to metastatic breast cancer presented during 2023.
•
Elacestrant (oral SERD) was approved in 2023 for the treatment of patients with pretreated ESR1 mutant HR-positive mBC.
•
Capivasertib (AKT inhibitor) was approved in 2023 for patients with pretreated mBC with PIK3CA, PTEN, or AKT1 alterations.
•
Sacituzumab govitecan was approved in 2023 for patients with HR-positive tumors previously tereated with chemotherapy.

Keywords: Advanced breast cancer; Breast cancer; Capivasertib; Datopotamab deruxtecan; Elacestrant; Metastatic breast cancer; Sacituzumab govitecan.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Triple Negative Breast Neoplasms* / drug therapy

Substances

Antineoplastic Agents